UZEDY®: Significant increase in sales in the United States in 2026

In the third quarter of 2026, net sales of UZEDY® saw a significant increase of 96% year-over-year, reaching $85 million in the United States. This performance led Teva Pharmaceuticals to revise its annual sales guidance for UZEDY® to a range of $290-310 million. For the first nine months of the year, sales totaled $225 million, surpassing the 2025 projections.

UZEDY® is recognized as the fastest-growing long-acting injectable antipsychotic treatment in the United States. Medincell receives royalties on these sales and can receive up to $105 million in commercial milestone payments.